Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant Nlrp3 Inhibitor Vtx3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.